Browsing Tag
Cologuard
4 posts
Abbott sales reach $13bn as Exact Sciences deal drives 47% diagnostics growth
Abbott Laboratories reported third-quarter revenue of $13.01 billion, supported by the acquisition of Exact Sciences and growth in cardiovascular and diabetes technologies. However, slower medical device momentum and a cautious annual outlook weighed on investor sentiment.
Abbott (ABT) stock surges 12% as Q2 earnings beat lifts 2026 EPS outlook to $5.45-$5.60
Abbott shares headed for their strongest daily gain in 24 years after the healthcare group beat second-quarter expectations and raised its adjusted earnings forecast.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Abbott expands diagnostics empire with $23bn takeover of cancer-test leader Exact Sciences
Find out how Abbott’s $23B acquisition of Exact Sciences could reshape cancer diagnostics and redefine growth in oncology screening.